Esmo 2019 Profound Trial

ESMO 2019 PROfound Trial

HPR

Expert comment: The PROfound trial | Eleni Efstathiou

Medicine Matters oncology

Andrea Necchi, ESMO 2019 - KEYNOTE-045 trial in advanced urothelial cancer

Touch Medical Media

Targeted therapy: Recent advances in prostate cancer from ESMO 2019

ESMO 2019: Dr. McGregor Highlights Impactful 2019 Prostate Cancer Studies

New Findings Could Change the Everyday Treatment of Patients With Advanced Prostate Cancer

Axel Merseburger, ESMO 2019 - Advances in metastatic hormone-sensitive prostate cancer

Touch Medical Media

Researcher comment: PROfound improvement in outcomes with olaparib in mCRPC | Maha Hussain

Medicine Matters oncology

All set for ESMO 2019!

Julie Graff, ESMO 2019 - KEYNOTE-641 study in prostate cancer

Touch Medical Media

PROfound: olaparib vs enzalutamide or abiraterone for mCRPC with HRR gene alterations

ESMO Congress 2019 Daily Reporter - Editor's Picks: Prostate cancer

European Society for Medical Oncology (ESMO)

PROfound: PARP inhibitor olaparib compared with new hormonal agents in advanced castration resis...

Prostate cancer updates: Advances in precision medicine and PARP inhibitors

PROfound Trial Shows Increased rPFS in mCRPC Patients with BRCA1, BRCA2, and ATM Mutations

Grand Rounds in Urology

Petros Grivas, ESMO 2019 - Advances in metastatic urothelial cancer

Touch Medical Media

ESMO 2019: Dr. O'Shaughnessy Highlights Progress in Breast Cancer

Arlene Siefker-Radtke, ESMO 2019 - KEYNOTE-866 Phase III trial in bladder cancer

Touch Medical Media

Highlights from ESMO 2019